These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20839307)

  • 41. Progress in Parkinson's disease-where do we stand?
    Toulouse A; Sullivan AM
    Prog Neurobiol; 2008 Aug; 85(4):376-92. PubMed ID: 18582530
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GM1 ganglioside in Parkinson's disease: Results of a five year open study.
    Schneider JS; Sendek S; Daskalakis C; Cambi F
    J Neurol Sci; 2010 May; 292(1-2):45-51. PubMed ID: 20206941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overcoming obstacles in Parkinson's disease.
    Sherer TB; Chowdhury S; Peabody K; Brooks DW
    Mov Disord; 2012 Nov; 27(13):1606-11. PubMed ID: 23115047
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson's disease.
    Zeiss CJ; Allore HG; Beck AP
    PLoS One; 2017; 12(2):e0171790. PubMed ID: 28182759
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Promising disease-modifying therapies for Parkinson's disease.
    Dawson VL; Dawson TM
    Sci Transl Med; 2019 Nov; 11(520):. PubMed ID: 31776289
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Disease modifying therapies III: Novel targets.
    Vijiaratnam N; Foltynie T
    Neuropharmacology; 2021 Dec; 201():108839. PubMed ID: 34656651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic.
    Kieburtz K; Katz R; McGarry A; Olanow CW
    Mov Disord; 2021 Jan; 36(1):59-63. PubMed ID: 33026697
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapies to Slow, Stop, or Reverse Parkinson's Disease.
    Foltynie T; Langston JW
    J Parkinsons Dis; 2018; 8(s1):S115-S121. PubMed ID: 30584162
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical trial end points: on the road to nowhere?
    Holloway RG; Dick AW
    Neurology; 2002 Mar; 58(5):679-86. PubMed ID: 11889228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Considerations for trials of disease modifying treatments in Parkinson disease.
    Ahlskog JE
    Neurology; 2020 Mar; 94(11):467-468. PubMed ID: 32102973
    [No Abstract]   [Full Text] [Related]  

  • 51. Moving Forward in Times of Crisis.
    Bloem BR; Brundin P
    J Parkinsons Dis; 2020; 10(3):747-748. PubMed ID: 32716323
    [No Abstract]   [Full Text] [Related]  

  • 52. Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations.
    Askanase AD; Furie RA; Dall'Era M; Bomback AS; Schwarting A; Zhao MH; Bruce IN; Khamashta M; Rubin B; Carroll A; Daniels M; Levy RA; van Vollenhoven R; Urowitz MB
    Lupus Sci Med; 2024 May; 11(1):. PubMed ID: 38777595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug reprofiling history and potential therapies against Parkinson's disease.
    Latif K; Ullah A; Shkodina AD; Boiko DI; Rafique Z; Alghamdi BS; Alfaleh MA; Ashraf GM
    Front Pharmacol; 2022; 13():1028356. PubMed ID: 36386233
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria.
    van Vollenhoven R; Askanase AD; Bomback AS; Bruce IN; Carroll A; Dall'Era M; Daniels M; Levy RA; Schwarting A; Quasny HA; Urowitz MB; Zhao MH; Furie R
    Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35346982
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The therapeutic role of minocycline in Parkinson's disease.
    Cankaya S; Cankaya B; Kilic U; Kilic E; Yulug B
    Drugs Context; 2019; 8():212553. PubMed ID: 30873213
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current Concepts in the Treatment of Multiple System Atrophy.
    Perez-Lloret S; Flabeau O; Fernagut PO; Pavy-Le Traon A; Rey MV; Foubert-Samier A; Tison F; Rascol O; Meissner WG
    Mov Disord Clin Pract; 2015 Mar; 2(1):6-16. PubMed ID: 30363880
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Substantia Nigra Free Water Increases Longitudinally in Parkinson Disease.
    Guttuso T; Bergsland N; Hagemeier J; Lichter DG; Pasternak O; Zivadinov R
    AJNR Am J Neuroradiol; 2018 Mar; 39(3):479-484. PubMed ID: 29419398
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.
    Zhang J; Tan LC
    Curr Neuropharmacol; 2016; 14(4):356-63. PubMed ID: 26644151
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How to optimize the treatment of early stage Parkinson's disease.
    Stocchi F; Vacca L; Radicati FG
    Transl Neurodegener; 2015; 4():4. PubMed ID: 25973179
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent developments in biomarkers in Parkinson disease.
    Schapira AH
    Curr Opin Neurol; 2013 Aug; 26(4):395-400. PubMed ID: 23823465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.